2025
Activation of macrophages by extracellular vesicles derived from Babesia-infected red blood cells
Hagos B, Brasov I, Branscome H, Rashid S, Bradford R, Leonelli J, Kashanchi F, Mamoun C, Molestina R. Activation of macrophages by extracellular vesicles derived from Babesia-infected red blood cells. Infection And Immunity 2025, 93: e00333-24. PMID: 40172538, PMCID: PMC12070731, DOI: 10.1128/iai.00333-24.Peer-Reviewed Original ResearchConceptsInfected red blood cellsPrimary cause of human babesiosisRed blood cellsExtracellular vesiclesActivated macrophagesResponse to <i>B.Host-pathogen interactionsModulation of pro-inflammatory cytokinesBlood cellsElimination of parasitesPro-inflammatory cytokinesActivation of NF-kBActivation of macrophagesRelease of extracellular vesiclesInnate immune responseIncubation of macrophagesUninfected RBCsCo-culture experimentsHuman babesiosisProtozoan parasitesCytokine secretionImmune responseMacrophage activationBabesiosisEV fractions
2024
Renal Angptl4 is a key fibrogenic molecule in progressive diabetic kidney disease
Srivastava S, Zhou H, Shenoi R, Morris M, Lainez-Mas B, Goedeke L, Rajendran B, Setia O, Aryal B, Kanasaki K, Koya D, Inoki K, Dardik A, Bell T, Fernández-Hernando C, Shulman G, Goodwin J. Renal Angptl4 is a key fibrogenic molecule in progressive diabetic kidney disease. Science Advances 2024, 10: eadn6068. PMID: 39630889, PMCID: PMC11616692, DOI: 10.1126/sciadv.adn6068.Peer-Reviewed Original ResearchConceptsAngiopoietin-like 4Diabetic kidney diseaseIntegrin B1Fibrogenic moleculesMutant miceSTING pathway activationIncreased fatty acid oxidationProgressive diabetic kidney diseaseDiabetic kidneyKidney diseaseReduced epithelial-to-mesenchymal transitionEpithelial-to-mesenchymal transitionFatty acid oxidationExpression of pro-inflammatory cytokinesTargeted pharmacological therapiesGene expressionMitochondrial damageEndothelial-to-mesenchymal transitionPro-inflammatory cytokinesPathway activationPharmacological therapyControl miceIntegrinAcid oxidationFibrogenic phenotypeGastrodenol suppresses NLRP3/GSDMD mediated pyroptosis and ameliorates inflammatory diseases
Chen P, Wang Y, Tang H, Liu Z, Wang J, Wang T, Xu Y, Ji S. Gastrodenol suppresses NLRP3/GSDMD mediated pyroptosis and ameliorates inflammatory diseases. Cellular Immunology 2024, 405: 104888. PMID: 39486308, DOI: 10.1016/j.cellimm.2024.104888.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsCytokinesEncephalomyelitis, Autoimmune, ExperimentalFemaleGasderminsHumansInflammasomesInflammationIntracellular Signaling Peptides and ProteinsLipopolysaccharidesMacrophagesMiceMice, Inbred C57BLNLR Family, Pyrin Domain-Containing 3 ProteinPeritonitisPhosphate-Binding ProteinsPyroptosisConceptsNucleotide-binding oligomerization domain-like receptor family pyrin domain-containing protein 3Caspase activationRecruitment domainNLRP3 oligomerizationPyrin domain-containing protein 3Gasdermin D (GSDMD)-mediated pyroptosisProtein 3PyroptosisSecretion of pro-inflammatory cytokinesOligomerizationHydrogen bondsApoptosis-associated speck like proteinInflammatory diseasesTherapeutic strategiesHelicobacter pyloriPro-inflammatory cytokinesCaspaseExperimental autoimmune encephalomyelitisLipopolysaccharide (LPS)-inducedProteinGasderminThe connection between sleep deficiency and coronary artery disease: Complexities and controversies
Ujjawal A, Lobo T, Yaggi H, Neeland I. The connection between sleep deficiency and coronary artery disease: Complexities and controversies. Progress In Cardiovascular Diseases 2024, 87: 83-89. PMID: 39384126, DOI: 10.1016/j.pcad.2024.10.002.Peer-Reviewed Original ResearchCoronary artery diseaseArtery diseaseBurden of coronary artery diseaseRisk of coronary artery diseaseActivation of pro-inflammatory cytokinesPathophysiology of coronary artery diseasePro-inflammatory cytokinesSleep deficiencyAssociation of sleepPathophysiological mechanismsNovel treatmentSleep physiologyEtiological relationshipDisease processSleepDiseaseDeficiencyPhysiological phenomenaMorbidityCytokinesPathophysiologyA Randomized Placebo-Controlled Trial of Leronlimab in Mild-To-Moderate COVID-19
Seethamraju H, Yang O, Loftus R, Ogbuagu O, Sammartino D, Mansour A, Sacha J, Ojha S, Hansen S, Arman A, Lalezari J. A Randomized Placebo-Controlled Trial of Leronlimab in Mild-To-Moderate COVID-19. Clinical Therapeutics 2024, 46: 891-899. PMID: 39353749, DOI: 10.1016/j.clinthera.2024.08.019.Peer-Reviewed Original ResearchMild to moderate COVID-19National Early Warning Score 2SARS-CoV-2 infectionPost Hoc AnalysisSARS-CoV-2Randomized placebo-controlled trialHoc AnalysisHuman IgG4 monoclonal antibodyModerate-to-severe diseaseViral replicationHIV-1 infectionPlacebo-controlled studyProduction of pro-inflammatory cytokinesExcessive production of pro-inflammatory cytokinesMild-to-moderateAdverse event ratesExploratory post hoc analysisTotal symptom scorePathophysiology of SARS-CoV-2 infectionPro-inflammatory cytokinesHeightened immune responsePathophysiology of COVID-19IgG4 monoclonal antibodyPlacebo groupDouble-blindMesenchymal stem cell-derived small extracellular vesicles alleviate the immunometabolic dysfunction in murine septic encephalopathy
Koutroulis I, Kratimenos P, Hoptay C, O’Brien W, Sanidas G, Byrd C, Triantafyllou M, Goldstein E, Jablonska B, Bharadwaj M, Gallo V, Freishtat R. Mesenchymal stem cell-derived small extracellular vesicles alleviate the immunometabolic dysfunction in murine septic encephalopathy. IScience 2024, 27: 110573. PMID: 39165840, PMCID: PMC11334791, DOI: 10.1016/j.isci.2024.110573.Peer-Reviewed Original ResearchCentral nervous systemSeptic encephalopathyStem cell (MSC)-derived small extracellular vesiclesSmall extracellular vesiclesDysregulated host response to infectionRestored aerobic metabolismLife-threatening organ dysfunctionLong-term sequelaeHost response to infectionExtracellular vesiclesMesenchymal stem cell-derived small extracellular vesiclesPro-inflammatory cytokinesCell-derived small extracellular vesiclesResponse to infectionStem cell-derived small extracellular vesiclesImmune dysregulationOrgan dysfunctionSusceptible to injurySeptic miceClinical symptomsClinical severityImmunometabolic dysfunctionIntravenous administrationDisease outcomeInfectious processInflammasomes in chronic liver disease: Hepatic injury, fibrosis progression and systemic inflammation
Taru V, Szabo G, Mehal W, Reiberger T. Inflammasomes in chronic liver disease: Hepatic injury, fibrosis progression and systemic inflammation. Journal Of Hepatology 2024, 81: 895-910. PMID: 38908436, PMCID: PMC11881887, DOI: 10.1016/j.jhep.2024.06.016.Peer-Reviewed Original ResearchAcute-on-chronic liver failureChronic liver diseaseLiver disease progressionToll-like receptorsLiver diseasePortal hypertensionLiver failureDisease progressionLiver injuryImmune systemEnd-stage liver diseaseRelease of pro-inflammatory cytokinesInnate immune cellsFlares of inflammationDysfunctional immune systemInflammasome activationPro-inflammatory stateNuclear factor kappa BPro-inflammatory cytokinesAdaptive immune systemFactor kappa BSystemic inflammationLiver parenchymal cellsWhite adipose tissueImmune cellsIs Lipid Metabolism of Value in Cancer Research and Treatment? Part II: Role of Specialized Pro-Resolving Mediators in Inflammation, Infections, and Cancer
Babar M, Nassar A, Nie X, Zhang T, He J, Yeung J, Norris P, Ogura H, Muldoon A, Chen L, Libreros S. Is Lipid Metabolism of Value in Cancer Research and Treatment? Part II: Role of Specialized Pro-Resolving Mediators in Inflammation, Infections, and Cancer. Metabolites 2024, 14: 314. PMID: 38921449, PMCID: PMC11205484, DOI: 10.3390/metabo14060314.Peer-Reviewed Original ResearchResolution of inflammationPro-resolving mediatorsTherapeutic effectOral squamous cell carcinomaT cell responsesSquamous cell carcinomaEicosapentaenoic acid derivativeExcessive neutrophil infiltrationDendritic cell migrationEndogenous lipid mediatorsMetastasis of cancer cellsPro-inflammatory cytokinesSpecialized pro-resolving mediatorsCell carcinomaTumor microenvironmentIschemia-related injuryLung inflammationTumor progressionNeutrophil infiltrationCell debris clearanceCystic fibrosisLung cancerAcute inflammationHerpes virusTherapeutic approachesSLAMF7+ CD8+ T cells exhibit decreased anti-tumor responses in renal cell carcinoma
Wirth L, Hugaboom M, Street K, Ruthen N, Jegede O, Schindler N, McDermott D, Plimack E, Sosman J, Haas N, Hurwitz M, Hammers H, Signoretti S, Atkins M, Wu C, Braun D. SLAMF7+ CD8+ T cells exhibit decreased anti-tumor responses in renal cell carcinoma. The Journal Of Immunology 2024, 212: 1491_5876-1491_5876. DOI: 10.4049/jimmunol.212.supp.1491.5876.Peer-Reviewed Original ResearchCD8+ T cellsImmune-checkpoint inhibitorsRenal cell carcinomaCD8+ T-cell effector functionT cell effector functionT cellsCell carcinomaResistance to immune-checkpoint inhibitorsEffector functionsPopulation of CD8+ T cellsCD3+ T cellsTreatment of renal cell carcinomaHealthy human PBMCTumor-infiltrating lymphocytesAnti-tumor responsesPatient T cellsReduction of pro-inflammatory cytokinesAnti-tumor functionPro-inflammatory cytokinesSingle-cell transcriptome analysisNivolumab monotherapySLAMF7 expressionClinical benefitGranzyme BIFN-gComplement protein signatures in patients with alcohol-associated hepatitis
Taiwo M, Huang E, Pathak V, Bellar A, Welch N, Dasarathy J, Streem D, McClain C, Mitchell M, Barton B, Szabo G, Dasarathy S, Consortium A, Schaefer E, Luther J, Day L, Ouyang X, Suyavaran A, Mehal W, Jacobs J, Goodman R, Rotroff D, Nagy L. Complement protein signatures in patients with alcohol-associated hepatitis. JCI Insight 2024, 9: e174127. PMID: 38573776, PMCID: PMC11141929, DOI: 10.1172/jci.insight.174127.Peer-Reviewed Original ResearchAlcohol-associated hepatitisSevere AHAlcohol use disorderAlcoholic cirrhosisHealthy controlsPredicting 90-day mortalityComplement proteinsSerum proteome of patientsEthanol-induced liver injurySerum proteomeDevelopment of effective therapiesProteome of patientsAssociated with pro-inflammatory cytokinesProtein signaturesPro-inflammatory cytokinesCoagulation factors IINon-invasive biomarkersDiagnostic challengeSerine protease 1Murine modelEffective therapyLiver injuryPrognostic biomarkerHepatic inflammationC1q binding proteinCompartment-specific regulation of NaV1.7 in sensory neurons after acute exposure to TNF-α
Tyagi S, Higerd-Rusli G, Ghovanloo M, Dib-Hajj F, Zhao P, Liu S, Kim D, Shim J, Park K, Waxman S, Choi J, Dib-Hajj S. Compartment-specific regulation of NaV1.7 in sensory neurons after acute exposure to TNF-α. Cell Reports 2024, 43: 113685. PMID: 38261513, PMCID: PMC10947185, DOI: 10.1016/j.celrep.2024.113685.Peer-Reviewed Original ResearchTNF-aSensory neuronsEffect of TNF-aSensory neuron excitabilityTumor necrosis factor-aRegulation of NaV1.7Voltage-gated sodiumPro-inflammatory cytokinesCompartment-specific effectsNeuronal plasma membraneSensitize nociceptorsNeuronal excitabilitySomatic membraneChannel N terminusElectrophysiological recordingsP38 MAPKIon channelsFactor AAcute exposureMolecular determinantsNeuronsAxonal endingsPhospho-acceptor sitesPlasma membraneCompartment-specific regulationExpression of Transcriptional Factors of T Helper Differentiation (T-bet, GATA-3, RORγt, and FOXP3), MIF Receptors (CD44, CD74, CXCR2, 4, 7), and Th1, Th2, and Th17 Cytokines in PBMC from Control Subjects and Rheumatoid Arthritis Patients
Zerpa-Hernández D, García-Chagollán M, Sánchez-Zuno G, García-Arellano S, Hernández-Bello J, Hernández-Palma L, Cerpa-Cruz S, Martinez-Bonilla G, Nicoletti F, Muñoz-Valle J. Expression of Transcriptional Factors of T Helper Differentiation (T-bet, GATA-3, RORγt, and FOXP3), MIF Receptors (CD44, CD74, CXCR2, 4, 7), and Th1, Th2, and Th17 Cytokines in PBMC from Control Subjects and Rheumatoid Arthritis Patients. 2024, 24: 1169-1182. PMID: 37807647, DOI: 10.2174/0115665240260976230925095330.Peer-Reviewed Original ResearchConceptsPeripheral blood mononuclear cellsMacrophage migration inhibitory factorT CD4+ lymphocytesMIF receptorRA patientsControl subjectsCS groupTh17 cytokinesRheumatoid arthritisElevated levels of pro-inflammatory cytokinesActivity of Foxp3Multiplex bead analysisLevels of pro-inflammatory cytokinesExpression of CXCR7Expression of CD74Expression of GATA3Levels of cytokinesT helper differentiationBlood mononuclear cellsPro-inflammatory cytokinesMigration inhibitory factorDevelopment of rheumatoid arthritisRheumatoid arthritis patientsProfile cytokinesTh17 responses
2023
Role of the immune-kynurenine pathway in treatment-resistant schizophrenia
Chen W, Tian Y, Gou M, Wang L, Tong J, Zhou Y, Feng W, Li Y, Chen S, Liu Y, Wang Z, Pan S, Zhang P, Huang J, Yang X, Li C, Tian L, Hong L, Tan Y. Role of the immune-kynurenine pathway in treatment-resistant schizophrenia. Progress In Neuro-Psychopharmacology And Biological Psychiatry 2023, 130: 110926. PMID: 38147973, DOI: 10.1016/j.pnpbp.2023.110926.Peer-Reviewed Original ResearchConceptsImmune-inflammatory response systemTreatment-resistant schizophreniaQUIN/KYNA ratioNon-TRS patientsHealthy controlsKynurenine pathwayKP metabolismKP activationKynurenic acidQuinolinic acidInflammation-related effectsPeripheral immune responseAnti-inflammatory cytokinesPro-inflammatory cytokinesBinary logistic regression analysisPathophysiology of schizophreniaLogistic regression analysisAge of onsetLower kynurenineKP metabolitesKYNA levelsIllness onsetPlasma levelsRisk factorsNMDA receptorsPlasma Human Immunodeficiency Virus 1 Soluble Glycoprotein 120 Association With Correlates of Immune Dysfunction and Inflammation in Antiretroviral Therapy–Treated Individuals With Undetectable Viremia
Benlarbi M, Richard J, Bourassa C, Tolbert W, Chartrand-Lefebvre C, Gendron-Lepage G, Sylla M, El-Far M, Messier-Peet M, Guertin C, Turcotte I, Fromentin R, Verly M, Prévost J, Clark A, Mothes W, Kaufmann D, Maldarelli F, Chomont N, Bégin P, Tremblay C, Baril J, Trottier B, Trottier S, Duerr R, Pazgier M, Durand M, Finzi A. Plasma Human Immunodeficiency Virus 1 Soluble Glycoprotein 120 Association With Correlates of Immune Dysfunction and Inflammation in Antiretroviral Therapy–Treated Individuals With Undetectable Viremia. The Journal Of Infectious Diseases 2023, 229: 763-774. PMID: 38035854, PMCID: PMC10938206, DOI: 10.1093/infdis/jiad503.Peer-Reviewed Original ResearchImmune dysfunctionAntiretroviral therapyUndetectable viremiaChronic inflammationAtherosclerotic plaquesSubclinical coronary artery diseaseSub-clinical cardiovascular diseaseCoronary artery diseasePro-inflammatory cytokinesCross-sectional assessmentCanadian HIVCD4 depletionCD4 countCD8 ratioDetectable viremiaArtery diseaseIL-6Soluble gp120Cardiovascular diseaseGp120 subunitImmunomodulatory propertiesAging CohortInflammationViremiaSgp120Advances in understanding and treating diabetic kidney disease: focus on tubulointerstitial inflammation mechanisms
Xu C, Ha X, Yang S, Tian X, Jiang H. Advances in understanding and treating diabetic kidney disease: focus on tubulointerstitial inflammation mechanisms. Frontiers In Endocrinology 2023, 14: 1232790. PMID: 37859992, PMCID: PMC10583558, DOI: 10.3389/fendo.2023.1232790.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsDiabetic kidney diseaseTubulointerstitial lesionsKidney diseaseInflammation mechanismsManagement of DKDEnd-stage kidney diseaseMineralocorticoid receptor antagonistsImmune-inflammatory mechanismsPro-inflammatory cytokinesAldosterone blockadeDKD outcomesInflammatory mechanismsSerious complicationsKidney functionGlomerular lesionsReceptor antagonistClinical trialsKidney volumeT cellsPreclinical studiesTubulointerstitial regionsLesionsTherapyDiseaseRecent studiesHuman mesenchymal stem‐derived extracellular vesicles improve body growth and motor function following severe spinal cord injury in rat
Nakazaki M, Lankford K, Yamamoto H, Mae Y, Kocsis J. Human mesenchymal stem‐derived extracellular vesicles improve body growth and motor function following severe spinal cord injury in rat. Clinical And Translational Medicine 2023, 13: e1284. PMID: 37323108, PMCID: PMC10272923, DOI: 10.1002/ctm2.1284.Peer-Reviewed Original ResearchConceptsSpinal cord injurySevere spinal cord injuryFunctional motor recoveryYoung adult ratsMotor recoveryMesenchymal stem/stromal cellsSmall extracellular vesiclesMSC-sEVsCord injuryM2 macrophagesMotor functionAdult ratsBody growthPro-inflammatory cytokine tumor necrosisAdult spinal cord injuryDay 7 post-SCISystemic pro-inflammatory cytokinesIGF-1 levelsPro-inflammatory cytokinesCytokine tumor necrosisSystemic serum levelsBroad therapeutic benefitsNormal body growthExtracellular vesiclesDifferent treatment groupsIL-10/IL-6 ratio from nasal & oral swab samples, acts as an inflammatory indicator for COVID-19 patients infected with the delta variant
Biswas B, Roy S, Banerjee I, Jana S, Bhattacharjee B, Chakraborty S, Mondal A, Goswami R. IL-10/IL-6 ratio from nasal & oral swab samples, acts as an inflammatory indicator for COVID-19 patients infected with the delta variant. Heliyon 2023, 9: e16985. PMID: 37292329, PMCID: PMC10238278, DOI: 10.1016/j.heliyon.2023.e16985.Peer-Reviewed Original ResearchViral load patientsCOVID-19 patientsNon-vaccinated patientsViral loadIL-10/IL-6 ratioHyper-inflammatory immune responseMultiple pro-inflammatory cytokinesCT valuesIL-10/IL-6Control groupSwab samplesPro-inflammatory cytokinesRelease of multiple pro-inflammatory cytokinesOral swab samplesUninfected donorsICU supportStatus of vaccinationNasal swab samplesInflammatory indicatorsDisease progressionCytokine markersPatientsNon-vaccinated COVID-19 patientsNasal swabsUninfected individualsOverproduction of Pro-inflammatory Cytokines in New-Onset Refractory Status Epilepticus (NORSE) (S35.002)
Hanin A, Cespedes J, Dorgham K, Gopaul M, Hafler D, Navarro V, Gaspard N, Hirsch L. Overproduction of Pro-inflammatory Cytokines in New-Onset Refractory Status Epilepticus (NORSE) (S35.002). Neurology 2023, 100 DOI: 10.1212/wnl.0000000000203729.Peer-Reviewed Original ResearchNew-onset refractory status epilepticusRefractory status epilepticusPro-inflammatory cytokinesStatus epilepticusInflammatory disequilibrium and lateral ventricular enlargement in treatment-resistant schizophrenia
Chen W, Gou M, Wang L, Li N, Li W, Tong J, Zhou Y, Xie T, Yu T, Feng W, Li Y, Chen S, Tian B, Tan S, Wang Z, Pan S, Luo X, Zhang P, Huang J, Tian L, Li C, Tan Y. Inflammatory disequilibrium and lateral ventricular enlargement in treatment-resistant schizophrenia. European Neuropsychopharmacology 2023, 72: 18-29. PMID: 37058967, DOI: 10.1016/j.euroneuro.2023.03.014.Peer-Reviewed Original ResearchConceptsAnti-inflammatory cytokinesInflammatory disequilibriumImmune-inflammatory response systemPlasma cytokine levelsTreatment-resistant schizophreniaLateral ventricular enlargementLarger lateral ventricle volumesPro-inflammatory cytokinesLateral ventricle volumeNegative Syndrome ScalePotential pathophysiological processesEnzyme-linked immunosorbentHigher PANSS scoresImmune imbalanceCytokine levelsT helperInflammatory imbalanceImmune biomarkersVentricular enlargementClinical manifestationsRegulatory cytokinesHealthy controlsPANSS scoresTh-17Subcortical volumesCytokines in New‐Onset Refractory Status Epilepticus Predict Outcomes
Hanin A, Cespedes J, Dorgham K, Pulluru Y, Gopaul M, Gorochov G, Hafler D, Navarro V, Gaspard N, Hirsch L. Cytokines in New‐Onset Refractory Status Epilepticus Predict Outcomes. Annals Of Neurology 2023, 94: 75-90. PMID: 36871188, DOI: 10.1002/ana.26627.Peer-Reviewed Original ResearchConceptsNew-onset refractory status epilepticusCytokines/chemokinesFebrile infection-related epilepsy syndromePro-inflammatory cytokines/chemokinesRefractory status epilepticusCerebrospinal fluidStatus epilepticusCryptogenic new-onset refractory status epilepticusSerum cytokines/chemokinesSpecific anti-inflammatory interventionsCytokine/chemokine levelsCytokine/chemokine profilesAnti-inflammatory interventionsCXCL8/ILLong-term outcomesPro-inflammatory cytokinesAnn NeurolChemokine levelsCytokine levelsChemokine profilesEpilepsy syndromesMIP-1αIL-6Predicts outcomeWorse outcomes
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply